Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes

Phase 0 Terminated 9 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Alliance for Cancer Gene Therapy · collab National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from cancer cells may help the body build an effective immune response to kill abnormal cells. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with myelodysplastic syndromes (MDS).

Timeline

Start: 2007-09
Primary completion: 2009-10
Completion: 2010-01

Outcome

Met primary endpoint

Stopped (Business): “Loss of funding”

paper The primary objective of safety was met as there were no serious adverse events. PMID 29616857 ↗

Publications

Results Robinson TM, Prince GT, Thoburn C, Warlick E, Ferguson A, Kasamon YL, Borrello IM, Hess A, Smith BD. Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma. 2018 Dec;59(12):2801-2811. doi: 10.1080/10428194.2018.1443449. Epub 2018 Apr 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	K562/GM-CSF cell vaccine	Vaccine	1e+08 cells	Subcutaneous